Ayala Pharmaceuticals Inc. (ADXS)
OTCMKTS: ADXS · Delayed Price · USD
0.640
-0.060 (-8.57%)
Mar 28, 2024, 3:03 PM EDT - Market closed
Ayala Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 - 2002 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.25 | 3.24 | 0.25 | 2.33 | 6.06 | 12.03 | 3.99 | 0 | 1 | 0 | Upgrade
|
Revenue Growth (YoY) | -92.28% | 1180.63% | -89.16% | -61.50% | -49.61% | 201.16% | - | - | - | - | Upgrade
|
Cost of Revenue | 0.31 | 3.71 | 1.29 | 1.29 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Gross Profit | -0.06 | -0.47 | -1.03 | 1.05 | 6.06 | 12.03 | 3.99 | 0 | 1 | 0 | Upgrade
|
Selling, General & Admin | 8.42 | 11.46 | 11.09 | 4.34 | 19.47 | 38.66 | 31.71 | 24.45 | 11.85 | 9.07 | Upgrade
|
Research & Development | 7.61 | 10.56 | 15.61 | 14.42 | 56.97 | 71.9 | 48.77 | 24.22 | 8.69 | 5.62 | Upgrade
|
Other Operating Expenses | 3.05 | -0 | -0 | 0 | -0.06 | -0 | -0 | -0.04 | 0.01 | -3.53 | Upgrade
|
Operating Expenses | 16.03 | 22.03 | 26.7 | 18.76 | 76.44 | 110.56 | 80.49 | 48.67 | 20.54 | 14.69 | Upgrade
|
Operating Income | -16.09 | -18.79 | -26.45 | -17.71 | -70.38 | -98.53 | -76.49 | -48.67 | -19.54 | -14.69 | Upgrade
|
Interest Income | 0.16 | 0.01 | 0.11 | 0.23 | 0.58 | 0.67 | 0.33 | 0.11 | 0.04 | 0.01 | Upgrade
|
Interest Expense | 0 | 0.26 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.99 | Upgrade
|
Other Expense / Income | -1.62 | -1.23 | 0.08 | - | -3.34 | -0.02 | -0.07 | 0.08 | -0.63 | 5.04 | Upgrade
|
Pretax Income | -14.31 | -17.81 | -26.42 | -17.49 | -66.47 | -97.84 | -76.09 | -48.64 | -18.88 | -20.71 | Upgrade
|
Income Tax | 0.05 | 0.05 | 0.05 | 0.31 | 0.05 | -4.4 | -2.54 | -1.61 | -2.36 | -0.73 | Upgrade
|
Net Income | -14.36 | -17.86 | -26.47 | -17.79 | -66.52 | -93.44 | -73.56 | -47.03 | -16.53 | -19.99 | Upgrade
|
Shares Outstanding (Basic) | 2 | 2 | 1 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 2 | 2 | 1 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Change | 12.70% | 111.61% | -91.11% | 19884.51% | 27.13% | 14.48% | 26.31% | 63.84% | 241.36% | 95.41% | Upgrade
|
EPS (Basic) | -7.90 | -11.07 | -34.71 | -2.07 | -1549.20 | -2766.57 | -2493.43 | -2013.75 | -1159.26 | -4786.12 | Upgrade
|
EPS (Diluted) | -7.90 | -11.07 | -34.71 | -2.07 | -1549.20 | -2766.57 | -2493.43 | -2013.75 | -1159.26 | -4786.12 | Upgrade
|
Free Cash Flow | -15.49 | -15.9 | -22.69 | -16.28 | -64.97 | -81.55 | -13.52 | -25.93 | -17.46 | -9.01 | Upgrade
|
Free Cash Flow Per Share | -8.51 | -9.85 | -29.75 | -1.90 | -1513.22 | -2414.54 | -458.30 | -1110.27 | -1224.93 | -2158.21 | Upgrade
|
Gross Margin | -25.60% | -14.44% | -407.91% | 44.94% | 100.00% | 100.00% | 100.00% | - | 100.00% | - | Upgrade
|
Operating Margin | -6436.00% | -579.81% | -10454.15% | -758.83% | -1160.79% | -818.95% | -1914.77% | - | -1953.86% | - | Upgrade
|
Profit Margin | -5743.60% | -551.30% | -10462.06% | -762.30% | -1097.06% | -776.62% | -1841.27% | - | -1652.53% | - | Upgrade
|
Free Cash Flow Margin | -6194.00% | -490.71% | -8967.59% | -697.51% | -1071.58% | -677.80% | -338.43% | - | -1746.13% | - | Upgrade
|
EBITDA | -15.78 | -18.77 | -24.39 | -17.56 | -72.28 | -97.43 | -76.03 | -48.36 | -19.29 | -18.04 | Upgrade
|
EBITDA Margin | -6310.40% | -579.20% | -9641.90% | -752.40% | -1192.12% | -809.80% | -1903.07% | - | -1929.27% | - | Upgrade
|
Depreciation & Amortization | 0.31 | 0.99 | 1.98 | 0.15 | 1.5 | 1.12 | 0.54 | 0.27 | 0.2 | 0.18 | Upgrade
|
EBIT | -16.09 | -19.76 | -26.37 | -17.71 | -73.78 | -98.55 | -76.56 | -48.62 | -19.5 | -18.22 | Upgrade
|
EBIT Margin | -6436.00% | -609.75% | -10423.72% | -758.83% | -1216.87% | -819.11% | -1916.50% | - | -1949.60% | - | Upgrade
|
Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.